Collecting Stem Cells in Patients With Waldenstrom's Macroglobulinemia
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00899119|
Recruitment Status : Unknown
Verified January 2008 by National Cancer Institute (NCI).
Recruitment status was: Recruiting
First Posted : May 12, 2009
Last Update Posted : December 18, 2013
RATIONALE: Collecting and storing stem cells to study in the laboratory may help doctors learn more about collecting stem cells from patients who have undergone treatment for Waldenstrom's macroglobulinemia.
PURPOSE: This laboratory study is collecting stem cells from patients with Waldenstrom's macroglobulinemia.
|Condition or disease||Intervention/treatment|
- Harvest and store adequate CD34+ stem cells from patients with Waldenstrom's macroglobulinemia (WM) for potential future use in transplantation strategies.
- Evaluate the ability to harvest stem cells after therapy for WM (e.g., fludarabine-based chemotherapy) by evaluating the number of days to adequate harvest.
- Collect aliquots of stem cells for future research analysis as part of a WM database project.
OUTLINE: Patients undergo collection of autologous stem cells beginning on day 4 or 5 and continuing until an adequate number of stem cells are collected. Cells are then cryopreserved.
PROJECTED ACCRUAL: A total of 40 patients will be accrued for this study.
|Study Type :||Observational|
|Estimated Enrollment :||40 participants|
|Official Title:||Autologous Stem Cell Harvesting for Waldenstrom's Macroglobulinemia|
|Study Start Date :||November 2005|
- Number of days to adequate stem cell harvest
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00899119
|United States, New York|
|Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center||Recruiting|
|New York, New York, United States, 10032|
|Contact: Clinical Trials Office - Herbert Irving Comprehensive Cancer C 212-305-8615|
|Study Chair:||Gwen L. Nichols, MD||Herbert Irving Comprehensive Cancer Center|